Melanie Senior, MSc (Cantab), MA
Melanie is a writer and analyst with nearly 20 years’ experience covering the life sciences industry. She writes regularly for Nature Biotechnology, IN VIVO and Medtech Strategist about science and technology, finance, strategy and market access. She has published numerous in-depth reports on key issues facing the industry, from real-world evidence to digital technology, AI and pricing pressure.
Melanie also works with companies, investors and associations to help formulate and communicate their strategies and strengths. Past and present clients include the BioIndustry Association, the Alliance for Regenerative Medicine, Bioscience Managers, MedCity, ThermoFisher, Cytel, Shire Pharmaceuticals and Informa Business Intelligence.
Outside of the UK, Melanie has worked with the Life Sciences team at EY and with French, German and Norwegian biotech and med-tech start-ups. She has also worked with US-based companies including market-access focused Real Endpoints.
Melanie has held various editorial positions within Elsevier, Windhover Information and at the Financial Times Group, where she began her career after gaining a first-class degree in Natural Sciences from Cambridge University.
Melanie continues to develop her understanding of health economics and science through post-graduate qualifications in International Health Technology Assessment (University of Sheffield) and Sports Nutrition (St. Mary’s University, Twickenham). She speaks fluent French and good German.